JP2010520174A5 - - Google Patents

Download PDF

Info

Publication number
JP2010520174A5
JP2010520174A5 JP2009551216A JP2009551216A JP2010520174A5 JP 2010520174 A5 JP2010520174 A5 JP 2010520174A5 JP 2009551216 A JP2009551216 A JP 2009551216A JP 2009551216 A JP2009551216 A JP 2009551216A JP 2010520174 A5 JP2010520174 A5 JP 2010520174A5
Authority
JP
Japan
Prior art keywords
dosage form
pyrrolidinone
pyridinyl
cyclobutyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009551216A
Other languages
English (en)
Japanese (ja)
Other versions
JP5743177B2 (ja
JP2010520174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/052430 external-priority patent/WO2008104590A2/en
Publication of JP2010520174A publication Critical patent/JP2010520174A/ja
Publication of JP2010520174A5 publication Critical patent/JP2010520174A5/ja
Application granted granted Critical
Publication of JP5743177B2 publication Critical patent/JP5743177B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009551216A 2007-03-01 2008-02-28 新規剤形 Expired - Fee Related JP5743177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89226707P 2007-03-01 2007-03-01
US60/892,267 2007-03-01
PCT/EP2008/052430 WO2008104590A2 (en) 2007-03-01 2008-02-28 Novel dosage form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014191832A Division JP2015038098A (ja) 2007-03-01 2014-09-19 新規剤形

Publications (3)

Publication Number Publication Date
JP2010520174A JP2010520174A (ja) 2010-06-10
JP2010520174A5 true JP2010520174A5 (cg-RX-API-DMAC7.html) 2011-04-21
JP5743177B2 JP5743177B2 (ja) 2015-07-01

Family

ID=39248198

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009551216A Expired - Fee Related JP5743177B2 (ja) 2007-03-01 2008-02-28 新規剤形
JP2014191832A Withdrawn JP2015038098A (ja) 2007-03-01 2014-09-19 新規剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014191832A Withdrawn JP2015038098A (ja) 2007-03-01 2014-09-19 新規剤形

Country Status (29)

Country Link
US (1) US20110014283A1 (cg-RX-API-DMAC7.html)
EP (1) EP2131818B1 (cg-RX-API-DMAC7.html)
JP (2) JP5743177B2 (cg-RX-API-DMAC7.html)
KR (1) KR101504371B1 (cg-RX-API-DMAC7.html)
CN (1) CN101674806B (cg-RX-API-DMAC7.html)
AR (1) AR065529A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008220795B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0807882A2 (cg-RX-API-DMAC7.html)
CA (1) CA2679529A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO6220900A2 (cg-RX-API-DMAC7.html)
CR (1) CR11013A (cg-RX-API-DMAC7.html)
DK (1) DK2131818T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000207A (cg-RX-API-DMAC7.html)
EA (1) EA019865B1 (cg-RX-API-DMAC7.html)
ES (1) ES2463468T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140390T1 (cg-RX-API-DMAC7.html)
IL (1) IL200619A (cg-RX-API-DMAC7.html)
MA (1) MA31198B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009009362A (cg-RX-API-DMAC7.html)
NZ (1) NZ579374A (cg-RX-API-DMAC7.html)
PE (1) PE20090114A1 (cg-RX-API-DMAC7.html)
PL (1) PL2131818T3 (cg-RX-API-DMAC7.html)
PT (1) PT2131818E (cg-RX-API-DMAC7.html)
SI (1) SI2131818T1 (cg-RX-API-DMAC7.html)
TW (1) TWI424856B (cg-RX-API-DMAC7.html)
UA (1) UA102515C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008104590A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200905866B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
JP5203360B2 (ja) 2006-06-23 2013-06-05 アボット・ラボラトリーズ ヒスタミンh3受容体調節剤としてのシクロプロピルアミン誘導体
US20110189280A1 (en) * 2008-08-29 2011-08-04 Allan James Clarke Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717618B1 (en) * 1993-09-03 2002-11-06 Smithkline Beecham Corporation Stabilized tablet formulation
IL143299A0 (en) * 1998-12-01 2002-04-21 Novo Nordisk As Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
TWI323256B (en) * 2002-12-20 2010-04-11 Glaxo Group Ltd Novel benzazepine derivatives and pharmaceutical compositions comprising said compounds
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
CA2531019A1 (en) * 2003-06-30 2005-01-06 Takeda Pharmaceutical Company Limited Preventive/remedy for urinary disturbance
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
PE20060302A1 (es) * 2004-06-18 2006-04-08 Glaxo Group Ltd Derivados de benzazepina como antagonistas del receptor h3
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2010520174A5 (cg-RX-API-DMAC7.html)
EP2391348B1 (en) Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
JP2010209104A5 (cg-RX-API-DMAC7.html)
HRP20140390T1 (hr) Novi oblik doziranja
CN1146558C (zh) 新的邦托拉唑盐
JP2013501718A5 (cg-RX-API-DMAC7.html)
MX2011000757A (es) Composicion farmaceutica.
JP2017088610A (ja) 7−[4−(4−ベンゾ[b]チオフェン−4−イル−ピペラジン−1−イル)ブトキシ]−1H−キノリン−2−オン又はその塩を含む錠剤
CN101633662A (zh) 普拉格雷的药用酸加成盐及其制备方法和药物应用
JP2020509059A (ja) バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
JP2007528876A5 (cg-RX-API-DMAC7.html)
CN104203244A (zh) 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物
CN101747305B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
JP6814886B2 (ja) ベンゾイミダゾール誘導体を含む新規な製剤
CN101541324B (zh) 医药组合物
CN104257622B (zh) 一种帕利哌酮控释片及其制备方法
HK1206352A1 (en) Means and method for treating solid tumours
JP2009541455A5 (cg-RX-API-DMAC7.html)
CN104650034A (zh) 一种稳定的阿西替尼化合物
CA2386716A1 (en) Magnesium salt of s-omeprazole
KR20150079449A (ko) 클로미프라민 함유 약학 조성물 및 이의 제조 방법
KR101524264B1 (ko) 발사르탄 함유 경구용 약학 조성물
JP7486258B2 (ja) 口腔内崩壊錠用顆粒、その製造方法および口腔内崩壊錠
CN109320553B (zh) 用于抗病毒的核苷类逆转录酶抑制剂
JP4826051B2 (ja) スチルベン誘導体の新規結晶及びその製造方法